DEBBY CARL: Open Payments
NPI 1891147104 · FORDLAND, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$760 in 42 payments from 14 companies in 2025. Trend: 2023 $616 · 2024 $858 · 2025 $760
Food & beverage: $760
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $199 |
| Novo Nordisk Inc | 7 | $117 |
| Otsuka America Pharmaceutical, Inc. | 5 | $110 |
| ABBVIE INC. | 3 | $61 |
| Insulet Corporation | 2 | $47 |
| AstraZeneca Pharmaceuticals LP | 3 | $42 |
| E.R. Squibb & Sons, L.L.C. | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $31 |
| Lundbeck LLC | 2 | $31 |
| Globus Medical, Inc. | 1 | $19 |
Products named: INGREZZA, REXULTI, Ozempic, VRAYLAR, Omnipod, COBENFY, XIFAXAN, AIRSUPRA.
Industry payments across MO — which companies pay providers there.
